ATYR aTyr Pharma, Inc.
aTyr Pharma, Inc. (ATYR) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $6.91 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -28.4% since its last earnings release on November 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About aTyr Pharma, Inc.
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.